1. Home
  2. VRTX vs LRCX Comparison

VRTX vs LRCX Comparison

Compare VRTX & LRCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • LRCX
  • Stock Information
  • Founded
  • VRTX 1989
  • LRCX 1980
  • Country
  • VRTX United States
  • LRCX United States
  • Employees
  • VRTX N/A
  • LRCX N/A
  • Industry
  • VRTX EDP Services
  • LRCX Industrial Machinery/Components
  • Sector
  • VRTX Technology
  • LRCX Technology
  • Exchange
  • VRTX Nasdaq
  • LRCX Nasdaq
  • Market Cap
  • VRTX 115.6B
  • LRCX 126.4B
  • IPO Year
  • VRTX 1991
  • LRCX N/A
  • Fundamental
  • Price
  • VRTX $470.43
  • LRCX $101.79
  • Analyst Decision
  • VRTX Buy
  • LRCX Buy
  • Analyst Count
  • VRTX 25
  • LRCX 25
  • Target Price
  • VRTX $508.91
  • LRCX $97.33
  • AVG Volume (30 Days)
  • VRTX 1.3M
  • LRCX 9.7M
  • Earning Date
  • VRTX 08-04-2025
  • LRCX 07-30-2025
  • Dividend Yield
  • VRTX N/A
  • LRCX 0.90%
  • EPS Growth
  • VRTX N/A
  • LRCX 32.12
  • EPS
  • VRTX N/A
  • LRCX 3.59
  • Revenue
  • VRTX $11,099,700,000.00
  • LRCX $17,135,705,000.00
  • Revenue This Year
  • VRTX $10.48
  • LRCX $24.90
  • Revenue Next Year
  • VRTX $10.69
  • LRCX $2.41
  • P/E Ratio
  • VRTX N/A
  • LRCX $28.35
  • Revenue Growth
  • VRTX 8.98
  • LRCX 20.32
  • 52 Week Low
  • VRTX $377.85
  • LRCX $56.32
  • 52 Week High
  • VRTX $519.88
  • LRCX $113.00
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 60.14
  • LRCX 76.82
  • Support Level
  • VRTX $455.79
  • LRCX $97.71
  • Resistance Level
  • VRTX $484.56
  • LRCX $99.50
  • Average True Range (ATR)
  • VRTX 8.51
  • LRCX 1.90
  • MACD
  • VRTX 3.43
  • LRCX 0.06
  • Stochastic Oscillator
  • VRTX 68.83
  • LRCX 98.80

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About LRCX Lam Research Corporation

Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

Share on Social Networks: